Clinical Trials Browser

OTHER × Has results × Everolimus × Clear all

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT03834740 2025-05-30

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Phase EARLY_PHASE1 Completed

27 enrolled 17 charts

Brain Neoplasms, Glioblastoma, Glioma

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors

NCT00113360 2025-05-01

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2 Completed

67 enrolled 6 charts

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed

10 enrolled 4 charts

Mastocytosis, Systemic

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms

NCT04339062 2025-04-23

CONTRAC

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

NCT02991807 2025-02-17

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Phase 1/2 Completed

46 enrolled 15 charts

Autistic Disorder, Hamartoma Syndrome, Multiple, Intellectual Disability

NCT03839940 2025-01-29

MIST

Phase 3 Terminated

39 enrolled 18 charts

Neoplasms

NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

21 enrolled 8 charts

Neuroendocrine Tumors

NCT01678664 2024-09-25

EVACEL

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00811590 2024-09-19

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Phase 2 Terminated

3 enrolled 4 charts

Neoplasms, Peutz-Jeghers Syndrome, Polyps

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02155920 2024-05-08

Everolimus for Children With Recurrent or Progressive Ependymoma

Phase 2 Completed

11 enrolled 13 charts

Familial ependymoma, Ependymoma

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT02332902 2023-12-20

DCLNF1

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

NCT01215136 2023-11-24

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

36 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast Neoplasms

NCT01642186 2022-12-29

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Phase 2 Completed

28 enrolled 13 charts

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT02023905 2022-12-29

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Phase 2 Terminated

27 enrolled 15 charts

Astrocytoma, Oligodendroglioma

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1/2 Terminated

26 enrolled 11 charts

Carcinoma, Renal Cell

NCT01034631 2022-07-11

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 Completed

154 enrolled 22 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00392821 2022-06-06

Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

Phase 1/2 Completed

78 enrolled 11 charts

Kidney Neoplasms

NCT01154335 2022-05-03

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Phase 1 Completed

18 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT01399918 2022-02-01

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

57 enrolled 10 charts

Carcinoma, Renal Cell

NCT02236572 2022-02-01

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2 Terminated

17 enrolled 11 charts

Breast Neoplasms

NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Phase 1 Completed

44 enrolled 9 charts

EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

NCT00591734 2021-11-24

RAD001 Plus Bevacizumab in Metastatic Melanoma

Phase 2 Completed

57 enrolled 7 charts

Melanoma

NCT00972335 2021-11-10

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase 2 Terminated

18 enrolled 5 charts

Meningioma

NCT01665768 2021-10-26

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Phase 2 Completed

56 enrolled 10 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT00936858 2021-10-22

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Phase 2 Completed

50 enrolled 14 charts

Thyroid Neoplasms

NCT02451696 2021-09-01

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Phase 2 Completed

15 enrolled 9 charts

Focal Cortical Dysplasia, Epilepsy, Tuberous Sclerosis

NCT01931163 2021-07-20

NECTAR

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 1/2 Terminated

23 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01125293 2021-04-23

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Terminated

46 enrolled 29 charts

Waldenstrom Macroglobulinemia

NCT01929642 2021-03-29

RAPT

Phase 2 Completed

3 enrolled 10 charts

Autistic Disorder, Tuberous Sclerosis, Self-Injurious Behavior

NCT01270321 2021-02-17

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Phase 2 Completed

42 enrolled 11 charts

Thyroid Neoplasms

NCT01051570 2020-12-01

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase 2 Completed

26 enrolled 9 charts

Prostatic Neoplasms

NCT02283658 2020-10-23

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2 Completed

20 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01075321 2020-10-22

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 1/2 Completed

58 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell